ASTCT® and CIBMTR® Bring Leading Experts Together to Share Groundbreaking Advancements in Hematopoietic Cell Transplantation, Cellular Therapy and Gene Therapy.
Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) were down 9.6% on Friday after Canaccord Genuity Group lowered their price target on the stock from $57.00 to $56.00.
Tandem Diabetes Care and Insulet executives this week touted the strong demand they’ve seen for their insulin pumps among people with Type 2 diabetes, tipping that adoption could be even greater ...